NCT05638880

Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Mostafa Bahaa · Academic / Other
• Sex: All
• Age: 40 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The prevalence of diabetes mellitus is increasing worldwide, and its complications are one of the leading causes of mortality from non-communicable diseases. Due to the high prevalence of diabetes and because 30-40% of diabetic patients \[both type 1 (T1DM) and type 2 (T2DM) diabetes mellitus\] develop kidney dysfunction, diabetic nephropathy (DN) is the main cause of end-stage renal disease worldwide. The renin-angiotensin-aldosterone system (RAAS), endothelin, and urotensin II are vasoactive hormones that have been extensively studied as other mediators although their relation to diabetic nephropathy is still speculative.

Conditions

• Diabetic Nephropathies

Interventions

Type	Name	Description
DRUG	Valsartan 80 mg	Valsartan is an angiotensin receptor blocker.
DRUG	Empagliflozin 10 MG	Empagliflozin is an oral hypoglycemic drug.
DRUG	Levocetirizine	Levocetirizine, Histamine-1 receptor antagonists provide a highly successful approach for controlling allergic and inflammatory conditions

Timeline

• Start date: 2022-12-20
• Primary completion: 2025-12-20
• Completion: 2025-12-20
• First posted: 2022-12-06
• Last updated: 2026-03-31

Locations

1 site across 1 country: Egypt